¿Cómo se compara el ratio PS de BMY con empresas similares?

BMY es un buen valor basado en su ratio Price-To-Sales (2.2x) comparado con la media de empresas similares (3.8x).

¿Cómo se compara el ratio PS de BMY con el de otras empresas de la industria European Pharmaceuticals ?

BMY es un buen valor basado en su ratio Price-To-Sales (2.2x) comparado con la media de la industria Swiss Pharmaceuticals (4.7x).

¿Cuál es el ratio PS de BMY comparado con su ratio PS justo? Este es el ratio PS esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

BMY es un buen valor basado en su ratio Price-To-Sales (2.2x) comparado con el ratio justo estimado Price-To-Sales (5.8x).

¿Cuál es el precio justo de BMY si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

BMY (CHF54.24) cotiza por debajo de nuestra estimación de [[valor justo]] (CHF165.01)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Bristol-Myers Squibb (BRSE:BMY) - Cotización, noticias y análisis

Resumen de acción BMY

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo. Saber más

Análisis fundamental de BMY
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	4/6
Rendimiento pasado	0/6
Salud financiera	3/6
Dividendos	5/6

Recompensas

Cotiza un 67.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 49.01%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Acciones altamente ilíquidas

Tiene un alto nivel de endeudamiento

El dividendo de 4.85% no está bien cubierto por los beneficios

Competidores de Bristol-Myers Squibb Company

Novartis

SWX:NOVN

CHF 185.4b

Roche Holding

SWX:ROG

CHF 210.3b

Galderma Group

SWX:GALD

CHF 20.3b

Sandoz Group

SWX:SDZ

CHF 17.1b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Bristol-Myers Squibb
Precios históricos de las acciones
Precio actual de la acción	US$54.24
Máximo en las últimas 52 semanas	US$0
Mínimo de 52 semanas	US$0
Beta	0.46
1Cambio en 1 mes	0%
Variación en 3 meses	0%
Cambio de 1 año	0%
3Variación en 3 años	22.19%
Variación en 5 años	22.19%
Variación desde la OPV	-0.75%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BMY	CH Pharmaceuticals	Mercado CH
7D	0%	-0.7%	-1.1%
1Y	0%	12.3%	8.2%

Rentabilidad vs. Industria: Los resultados de BMY fueron inferiores a los de la industria Swiss Pharmaceuticals, que obtuvo un rendimiento del 12.3% el año pasado.

Rentabilidad vs. Mercado: BMY obtuvo unos resultados inferiores a los del mercado Swiss, que fueron del 8.2% el año pasado.

Volatilidad de los precios

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	3.0%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	6.9%
10% least volatile stocks in CH Market	1.6%

Precio estable de las acciones: BMY no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BMY en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company descubre, desarrolla, licencia, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en todo el mundo. Ofrece productos para enfermedades hematológicas, oncológicas, cardiovasculares, inmunológicas, fibróticas y neurocientíficas. Los productos de la empresa incluyen Eliquis para la reducción del riesgo de ictus/embolia sistémica en la fibrilación auricular no valvular, y para el tratamiento de la TVP/EP; Opdivo para diversas indicaciones contra el cáncer, como el de vejiga, sangre, CCR, cabeza y cuello, CCR, CHC, pulmón, melanoma, MPM, estómago y esófago; Pomalyst/Imnovid para el mieloma múltiple; Orencia para la artritis reumatoide activa y la artritis psoriásica; y Sprycel para el tratamiento de la leucemia mieloide crónica con cromosoma Filadelfia positivo.

Resumen de fundamentos de Bristol-Myers Squibb Company

¿Cómo se comparan los beneficios e ingresos de Bristol-Myers Squibb con su capitalización de mercado?
Estadísticas fundamentales de BMY
Capitalización bursátil	CHF 84.96b
Beneficios(TTM)	-CHF 5.54b
Ingresos (TTM)	CHF 39.38b

2.2x

Ratio precio-ventas (PS)

-15.3x

Ratio precio-beneficio (PE)

¿Está BMY sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BMY
Ingresos	US$46.51b
Coste de los ingresos	US$11.08b
Beneficio bruto	US$35.43b
Otros gastos	US$41.97b
Beneficios	-US$6.54b

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

Oct 31, 2024

Beneficios por acción (BPA)	-3.23
Margen bruto	76.18%
Margen de beneficio neto	-14.06%
Ratio deuda/patrimonio	306.9%

¿Cómo se ha desempeñado BMY a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

4.8%

Rentabilidad actual por dividendo

-74%

Ratio de pagos

¿Paga BMY dividendos fiables?

Ver historial de dividendos e índices de referencia de BMY

¿Cuándo hay que comprar BMY para recibir un próximo dividendo?
fechas de dividendos de Bristol-Myers Squibb
Fecha ex dividendo	Oct 04 2024
Fecha de pago de dividendos	Nov 01 2024
Días hasta ex dividendo	43 days
Días hasta la fecha de pago de dividendos	15 days

¿Paga BMY dividendos fiables?

Ver historial de dividendos e índices de referencia de BMY

Resumen de acción BMY

Recompensas

Análisis de riesgos

Competidores de Bristol-Myers Squibb Company

SWX:NOVN

CHF 185.4b

SWX:ROG

CHF 210.3b

SWX:GALD

CHF 20.3b

SWX:SDZ

CHF 17.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Recent updates

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023)

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

Fourth quarter dividend of US$0.60 announced

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Full year 2023 earnings released: EPS: US$3.88 (vs US$2.97 in FY 2022)

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers